002020 京新药业
已收盘 06-01 15:00:00
资讯
新帖
简况
股市必读：京新药业（002020）5月29日董秘有最新回复
证券之星 · 06-01 03:06
股市必读：京新药业（002020）5月29日董秘有最新回复
新股消息 | 京新药业(002020.SZ)拟港股IPO 中国证监会要求补充说明境外子公司涉及的境外投资等监管程序履行情况
智通财经 · 05-29
新股消息 | 京新药业(002020.SZ)拟港股IPO 中国证监会要求补充说明境外子公司涉及的境外投资等监管程序履行情况
京新药业：地达西尼和JX2201的对外授权工作在积极推进中
证券之星 · 05-29
京新药业：地达西尼和JX2201的对外授权工作在积极推进中
京新药业：JX2201降脂新药已经完成了临床I期
证券之星 · 05-29
京新药业：JX2201降脂新药已经完成了临床I期
股市必读：京新药业（002020）5月22日董秘有最新回复
证券之星 · 05-25
股市必读：京新药业（002020）5月22日董秘有最新回复
京新药业：公司的仿制药希望可以借助集采增加销量，从而保持业绩稳定增长
证券之星 · 05-22
京新药业：公司的仿制药希望可以借助集采增加销量，从而保持业绩稳定增长
京新药业：公司主要基于商业化和管线优先级考虑
证券之星 · 05-22
京新药业：公司主要基于商业化和管线优先级考虑
京新药业：公司的降脂新药JX2201临床II期在推进中
证券之星 · 05-22
京新药业：公司的降脂新药JX2201临床II期在推进中
京新药业：公司地达西尼海外授权工作在积极推进中
证券之星 · 05-22
京新药业：公司地达西尼海外授权工作在积极推进中
京新药业：领雁项目在正常推进中
证券之星 · 05-22
京新药业：领雁项目在正常推进中
京新药业（002020）披露2025年度股东会决议公告，5月18日股价下跌2.25%
证券之星 · 05-18
京新药业（002020）披露2025年度股东会决议公告，5月18日股价下跌2.25%
股市必读：京新药业（002020）5月14日披露最新机构调研信息
证券之星 · 05-15
股市必读：京新药业（002020）5月14日披露最新机构调研信息
股市必读：京新药业（002020）5月8日董秘有最新回复
证券之星 · 05-11
股市必读：京新药业（002020）5月8日董秘有最新回复
京新药业：公司启动H股上市计划与创新转型战略相匹配
证券之星 · 05-09
京新药业：公司启动H股上市计划与创新转型战略相匹配
京新药业：员工持股计划业绩考核以扣非净利润为依据
证券之星 · 05-09
京新药业：员工持股计划业绩考核以扣非净利润为依据
京新药业：公司的盐酸卡立哌嗪胶囊在正常审批中
证券之星 · 05-09
京新药业：公司的盐酸卡立哌嗪胶囊在正常审批中
京新药业：深圳巨烽在国内医疗影像显示终端的市场占有率较高
证券之星 · 05-09
京新药业：深圳巨烽在国内医疗影像显示终端的市场占有率较高
每周股票复盘：京新药业（002020）将举行2025年度网上业绩说明会
证券之星 · 05-03
每周股票复盘：京新药业（002020）将举行2025年度网上业绩说明会
京新药业（002020）披露2025年度网上业绩说明会安排，4月30日股价下跌1.07%
证券之星 · 04-30
京新药业（002020）披露2025年度网上业绩说明会安排，4月30日股价下跌1.07%
【机构调研记录】浙商基金调研京新药业、我武生物
证券之星 · 04-27
【机构调研记录】浙商基金调研京新药业、我武生物
加载更多
公司概况
公司名称：
浙江京新药业股份有限公司
所属行业：
医药制造业
上市日期：
2004-07-15
主营业务：
浙江京新药业股份有限公司的主营业务是化学制剂、传统中药、生物制剂、化学原料药、医疗器械的研发、生产及销售。公司的主要产品是化学制剂、中成药、生物制剂、化学原料药、医疗器械。公司是第一批“中国医药企业制剂国际化先导企业”，连续多年荣登“中国化学制药行业制剂出口型优秀企业品牌”、“中国医药工业百强”和“中国化学制药企业百强榜”。
发行价格：
10.05
{"stockData":{"symbol":"002020","market":"SZ","secType":"STK","nameCN":"京新药业","latestPrice":13.47,"timestamp":1780297419000,"preClose":13.44,"halted":0,"volume":8562475,"delay":0,"changeRate":0.0022,"floatShares":724000000,"shares":861000000,"eps":0.8826,"marketStatus":"已收盘","change":0.03,"latestTime":"06-01 15:00:00","open":13.5,"high":13.62,"low":13.34,"amount":115000000,"amplitude":0.0208,"askPrice":13.48,"askSize":130,"bidPrice":13.47,"bidSize":37,"shortable":0,"etf":0,"ttmEps":0.8826,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780363800000},"marketStatusCode":5,"adr":0,"adjPreClose":13.44,"symbolType":"stock","openAndCloseTimeList":[[1780277400000,1780284600000],[1780290000000,1780297200000]],"highLimit":14.78,"lowLimit":12.1,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":861029140,"isCdr":false,"pbRate":1.9,"roa":"--","peRate":15.261727,"roe":"2.76%","epsLYR":0.92,"committee":-0.068087,"marketValue":11598000000,"turnoverRate":0.0118,"status":0,"floatMarketCap":9752000000},"requestUrl":"/m/hq/s/002020","defaultTab":"news","newsList":[{"id":"2640798559","title":"股市必读：京新药业（002020）5月29日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2640798559","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640798559?lang=zh_cn&edition=full","pubTime":"2026-06-01 03:06","pubTimestamp":1780254374,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，京新药业报收于13.44元，上涨1.66%，换手率1.85%，成交量13.41万手，成交额1.79亿元。董秘最新回复投资者： 问吕董，公司在业绩说明会上承诺核实公司二级市场是否被部分股东恶意对倒控制情况，问到底核实了吗？当日关注点来自交易信息汇总：5月29日主力资金净流入833.34万元，占总成交额4.65%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100001315.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639624277","title":"新股消息 | 京新药业(002020.SZ)拟港股IPO 中国证监会要求补充说明境外子公司涉及的境外投资等监管程序履行情况","url":"https://stock-news.laohu8.com/highlight/detail?id=2639624277","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639624277?lang=zh_cn&edition=full","pubTime":"2026-05-29 19:21","pubTimestamp":1780053712,"startTime":"0","endTime":"0","summary":"中国证监会国际司共对11家企业出具补充材料要求。其中，要求京新药业补充说明公司境外子公司涉及的境外投资、外汇管理等监管程序具体履行情况。招股书显示，京新药业是一家以创新为驱动力的制药集团，策略重点专注于两大核心疾病领域：中枢神经系统疾病；及心血管及脑血管疾病。近年，公司已将创新药研发的战略重点锁定于中枢神经系统疾病及心血管与脑血管疾病领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447924.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","BK4588","002020","BK4585","BK0239","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639612783","title":"京新药业：地达西尼和JX2201的对外授权工作在积极推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2639612783","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639612783?lang=zh_cn&edition=full","pubTime":"2026-05-29 08:12","pubTimestamp":1780013533,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)05月29日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司半年内市值急转急下，请问公司有无做好市值管理，针对地达西尼，JX2201等产品授权情况能否及时披露，这样太伤各位股东的信任了！京新药业回复：您好！谢谢您对公司的关注，公司的地达西尼和JX2201的对外授权工作在积极推进中，若情况落地，公司会根据信息披露要求及时披露，积极向投资者传递公司的经营进展。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900007871.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639612715","title":"京新药业：JX2201降脂新药已经完成了临床I期","url":"https://stock-news.laohu8.com/highlight/detail?id=2639612715","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639612715?lang=zh_cn&edition=full","pubTime":"2026-05-29 08:12","pubTimestamp":1780013533,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)05月29日在投资者关系平台上答复投资者关心的问题。投资者提问：问吕董，为什么公司回复问题都不具体回答？问降脂创新药一期临床结束，效果如何？你们怎么回复的，正在二期临床京新药业回复：您好！JX2201降脂新药已经完成了临床I期，现在在积极推进临床II期中，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900007873.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638046113","title":"股市必读：京新药业（002020）5月22日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2638046113","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638046113?lang=zh_cn&edition=full","pubTime":"2026-05-25 01:55","pubTimestamp":1779645312,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，京新药业报收于13.82元，下跌2.26%，换手率1.36%，成交量9.81万手，成交额1.37亿元。董秘最新回复投资者： 问吕董，那公司官网上说地达西尼成功实献海外授权？为何年报中未曾提及？领雁项目在正常推进中。今年有何计划董秘： 您好！人工大血管项目在临床中。公司降脂新药JX2201目前临床II期推进中，同时对外授权工作也在推进中。投资者： 2201管线已经二期，为何不公告一期临床数据情况？首付款金额和合作方有无框架预期？","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500000811.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637011318","title":"京新药业：公司的仿制药希望可以借助集采增加销量，从而保持业绩稳定增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2637011318","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637011318?lang=zh_cn&edition=full","pubTime":"2026-05-22 18:03","pubTimestamp":1779444198,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)05月22日在投资者关系平台上答复投资者关心的问题。投资者提问：公司2025年经营现金流7.81亿元，连续两个季度营收下滑，2026年Q1营收-3.46%。管理层认为营收何时能恢复正增长？仿制药存量下滑是否接近尾声？京新药业回复：您好！公司的仿制药希望可以借助集采增加销量，从而保持业绩稳定增长；同时，公司也会努力推进地达西尼的商业化，希望提升创新药营收在公司总收入中的占比。谢谢！以上内容为证券之星据公开信息整理，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200035909.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637313810","title":"京新药业：公司主要基于商业化和管线优先级考虑","url":"https://stock-news.laohu8.com/highlight/detail?id=2637313810","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637313810?lang=zh_cn&edition=full","pubTime":"2026-05-22 18:00","pubTimestamp":1779444050,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)05月22日在投资者关系平台上答复投资者关心的问题。投资者提问：JX11502临床暂停的具体原因是什么？是数据不及预期需要调整方案，还是战略优化？恢复时间节点有无预期？京新药业回复：您好！公司主要基于商业化和管线优先级考虑。谢谢！以上内容为证券之星据公开信息整理，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200035828.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637138633","title":"京新药业：公司的降脂新药JX2201临床II期在推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2637138633","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637138633?lang=zh_cn&edition=full","pubTime":"2026-05-22 18:00","pubTimestamp":1779444050,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)05月22日在投资者关系平台上答复投资者关心的问题。投资者提问：2201管线已经二期，为何不公告一期临床数据情况？京新药业回复：您好!公司的降脂新药JX2201临床II期在推进中。谢谢！以上内容为证券之星据公开信息整理，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200035826.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637318044","title":"京新药业：公司地达西尼海外授权工作在积极推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2637318044","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637318044?lang=zh_cn&edition=full","pubTime":"2026-05-22 18:00","pubTimestamp":1779444048,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)05月22日在投资者关系平台上答复投资者关心的问题。投资者提问：问吕董，公司官网3月4日的新春开门红中明确说地达西尼已成功实献海外授权，而公司每次互动中回复没有，到底什么情况？京新药业回复：您好！公司地达西尼海外授权工作在积极推进中，希望可以拓宽地达西尼的业绩贡献能力。谢谢！以上内容为证券之星据公开信息整理，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200035822.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637098318","title":"京新药业：领雁项目在正常推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2637098318","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637098318?lang=zh_cn&edition=full","pubTime":"2026-05-22 18:00","pubTimestamp":1779444048,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)05月22日在投资者关系平台上答复投资者关心的问题。投资者提问：既然回复说领雁项目未暂停，那么请问这个项目目前进展如何？今年有个计划？为何年报中未曾提及？京新药业回复：您好!领雁项目在正常推进中。谢谢！以上内容为证券之星据公开信息整理，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200035818.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636217210","title":"京新药业（002020）披露2025年度股东会决议公告，5月18日股价下跌2.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636217210","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636217210?lang=zh_cn&edition=full","pubTime":"2026-05-18 17:49","pubTimestamp":1779097752,"startTime":"0","endTime":"0","summary":"截至2026年5月18日收盘，京新药业报收于13.93元，较前一交易日下跌2.25%，最新总市值为119.94亿元。该股当日开盘14.22元，最高14.22元，最低13.88元，成交额达1.31亿元，换手率为1.29%。近日，浙江京新药业股份有限公司发布《2025年度股东会决议公告》。律师对本次会议出具法律意见书，认为会议决议合法有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800028323.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635747686","title":"股市必读：京新药业（002020）5月14日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2635747686","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635747686?lang=zh_cn&edition=full","pubTime":"2026-05-15 02:13","pubTimestamp":1778782390,"startTime":"0","endTime":"0","summary":"截至2026年5月14日收盘，京新药业报收于14.32元，下跌1.92%，换手率1.27%，成交量9.21万手，成交额1.33亿元。地达西尼2025年销售达成为1.95亿元，2026年预计在此基础上保持良好增长；2025年累计入院超过3000家，当前入院放量节奏符合并略超前期预期。2026年一季度，地达西尼销售延续2025年放量趋势，同比与环比均实现增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500001755.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634429638","title":"股市必读：京新药业（002020）5月8日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2634429638","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634429638?lang=zh_cn&edition=full","pubTime":"2026-05-11 03:58","pubTimestamp":1778443091,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，京新药业报收于15.05元，上涨0.2%，换手率1.75%，成交量12.67万手，成交额1.9亿元。董秘最新回复投资者： 问吕董，公司那么多现金为什么不把巨烽显示公司做大做强，并购一些前沿科技公司助力公司医疗器械更上一层楼。公司H股上市事项在正常推进中。公司启动H股上市计划与创新转型战略相匹配，坚持研发投入，做好创新布局。公司未有上述交易，相关情况敬请关注相关公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100001823.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634999674","title":"京新药业：公司启动H股上市计划与创新转型战略相匹配","url":"https://stock-news.laohu8.com/highlight/detail?id=2634999674","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634999674?lang=zh_cn&edition=full","pubTime":"2026-05-09 10:51","pubTimestamp":1778295067,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)05月09日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司既然有资金理财，为何还要到h股市场融资？京新药业回复：您好！公司启动H股上市计划与创新转型战略相匹配，坚持研发投入，做好创新布局。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050900005141.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634499964","title":"京新药业：员工持股计划业绩考核以扣非净利润为依据","url":"https://stock-news.laohu8.com/highlight/detail?id=2634499964","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634499964?lang=zh_cn&edition=full","pubTime":"2026-05-09 10:51","pubTimestamp":1778295067,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)05月09日在投资者关系平台上答复投资者关心的问题。投资者提问：问吕董，如果公司H股上市那么公司股权激励后续条件如何变化，难道还是公司利润总额吗？还是每股利润增长每年不低于10%？京新药业回复：您好！公司的员工持股计划公司层面的业绩考核指标是以经审计的归属于上市公司股东的扣除非经常性损益后的净利润为计算依据，相关具体内容敬请查看相关公告。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050900005139.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634999654","title":"京新药业：公司的盐酸卡立哌嗪胶囊在正常审批中","url":"https://stock-news.laohu8.com/highlight/detail?id=2634999654","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634999654?lang=zh_cn&edition=full","pubTime":"2026-05-09 10:48","pubTimestamp":1778294889,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)05月09日在投资者关系平台上答复投资者关心的问题。投资者提问：问吕董，盐酸卡立㖘嗪移出任务公示已两个多月了，移出任务公示栏后药监局审核法定工作曰不超20天？到底公司在干什么？京新药业回复：您好!公司的盐酸卡立哌嗪胶囊在正常审批中，也在相关公示名单中。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050900005120.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634499962","title":"京新药业：深圳巨烽在国内医疗影像显示终端的市场占有率较高","url":"https://stock-news.laohu8.com/highlight/detail?id=2634499962","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634499962?lang=zh_cn&edition=full","pubTime":"2026-05-09 10:48","pubTimestamp":1778294889,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)05月09日在投资者关系平台上答复投资者关心的问题。投资者提问：问吕董，公司那么多现金为什么不把巨烽显示公司做大做强，并购一些前沿科技公司助力公司医疗器械更上一层楼。或分拆上市！京新药业回复：您好！深圳巨烽在国内医疗影像显示终端的市场占有率较高，是全球主流大设备厂商的战略合作伙伴。公司会持续推进巨烽的发展。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050900005119.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239","159891"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632736677","title":"每周股票复盘：京新药业（002020）将举行2025年度网上业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2632736677","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632736677?lang=zh_cn&edition=full","pubTime":"2026-05-03 06:13","pubTimestamp":1777759993,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，京新药业报收于14.78元，较上周的15.39元下跌3.96%。本周，京新药业4月27日盘中最高价报15.53元。京新药业当前最新总市值127.26亿元，在化学制药板块市值排名45/150，在两市A股市值排名1651/5200。本周关注点公司公告汇总：京新药业将于2026年5月14日举行2025年度网上业绩说明会。为便于投资者了解公司2025年度经营情况，公司将于2026年5月14日下午15:00至17:00通过深圳交易所“互动易”平台“云访谈”栏目举行2025年度网上业绩说明会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300001472.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631103682","title":"京新药业（002020）披露2025年度网上业绩说明会安排，4月30日股价下跌1.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631103682","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631103682?lang=zh_cn&edition=full","pubTime":"2026-04-30 17:54","pubTimestamp":1777542899,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，京新药业报收于14.78元，较前一交易日下跌1.07%，最新总市值为127.26亿元。京新药业于2026年4月30日发布《关于举行2025年度网上业绩说明会的公告》。公告显示，公司已于2026年4月24日在巨潮资讯网披露《2025年年度报告》及其摘要；为便于投资者了解公司2025年度经营情况，公司将于2026年5月14日下午15:00至17:00通过深圳交易所“互动易”平台“云访谈”栏目举行2025年度网上业绩说明会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000058086.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630324103","title":"【机构调研记录】浙商基金调研京新药业、我武生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2630324103","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630324103?lang=zh_cn&edition=full","pubTime":"2026-04-27 08:03","pubTimestamp":1777248184,"startTime":"0","endTime":"0","summary":"2）我武生物 调研纪要：公司2026年一季度营收利润增长，得益于销售管理优化与市场推广加强。浙商基金成立于2010年，截至目前，资产管理规模292.67亿元，排名105/212；资产管理规模213.59亿元，排名103/212；管理公募基金数74只，排名83/212；旗下公募基金经理14人，排名93/212。旗下最近一年表现最佳的公募基金产品为浙商智选经济动能混合A，最新单位净值为0.93，近一年增长54.58%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700007405.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300357","002020"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1780337488329,"stockEarnings":[{"period":"1week","weight":-0.003},{"period":"1month","weight":-0.0886},{"period":"3month","weight":-0.1349},{"period":"6month","weight":-0.297},{"period":"1year","weight":0.0282},{"period":"ytd","weight":-0.2903}],"compareEarnings":[{"period":"1week","weight":-0.0228},{"period":"1month","weight":-0.0132},{"period":"3month","weight":-0.0158},{"period":"6month","weight":0.0463},{"period":"1year","weight":0.2122},{"period":"ytd","weight":0.0224}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江京新药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"31813人(较上一季度减少79.43%)","perCapita":"0股","listingDate":"2004-07-15","address":"浙江省绍兴市新昌县羽林街道新昌大道东路800号","registeredCapital":"86102万元","survey":" 浙江京新药业股份有限公司的主营业务是化学制剂、传统中药、生物制剂、化学原料药、医疗器械的研发、生产及销售。公司的主要产品是化学制剂、中成药、生物制剂、化学原料药、医疗器械。公司是第一批“中国医药企业制剂国际化先导企业”，连续多年荣登“中国化学制药行业制剂出口型优秀企业品牌”、“中国医药工业百强”和“中国化学制药企业百强榜”。","listedPrice":10.05},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"京新药业(002020)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供京新药业(002020)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"京新药业,002020,京新药业股票,京新药业股票老虎,京新药业股票老虎国际,京新药业行情,京新药业股票行情,京新药业股价,京新药业股市,京新药业股票价格,京新药业股票交易,京新药业股票购买,京新药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"京新药业(002020)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供京新药业(002020)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}